In addition, Verve is developing VERVE-201, which targets ANGPTL3, offering an alternative therapeutic strategy focused on remnant cholesterol metabolism in patients with refractory hypercholesterolemia. Here, ANGPTL3 is linked to Hypercholesterolemia.